Offering adjuvant pembrolizumab is now the standard of care in patients who are at risk of relapse after surgery. This recording organised by the European School of Urology (ESU) and the EAU Guidelines Office will provide you with crucial information on the treatment.
In this recording, you will:
- Discover the basis for the recommendation.
- Learn about optimising patient selection.
- Gain insights into how to discuss the treatment with patients.
- Know more about the impact of adjuvant use of pembrolizumab on overall therapy management.
Leading experts will also provide essential updates on adjuvant immune checkpoint inhibitor therapy in renal cell cancer (RCC).
Join and strengthen your knowledge in managing relapse in patients treated with adjuvant pembrolizumab.
Speakers:
- Prof. A. Bex (GB)
- Prof. Dr. J. Bedke (DE)
- Prof. Dr. T. Powles (GB)
- Dr. V. Grünwald (DE)
This recording is brought to you in collaboration with the EAU Guidelines Office.
🌟 Important info: The recording of this webinar is not EU-ACME accredited. Missed the live session? Earn 1 CME point by completing our online e-course at: https://uroweb.org/education-events/education?page=1&type=e-course. Don’t miss this opportunity! 🎓💡